QuidelOrtho (QDEL) has released an update.
QuidelOrtho Corporation has revealed its financial outcomes for Q4 and the entire year of 2023, along with adjusted projections for 2024. The updated 2024 financial guidance anticipates total revenues between $2.76 and $3.07 billion, with non-respiratory revenue contributing $2.30 to $2.34 billion, and respiratory revenue between $460 and $730 million. Adjusted EBITDA is expected to range from $565 to $720 million, which translates to 21-24% of their total revenue, while adjusted diluted EPS is projected to be between $1.88 and $3.60.
For further insights into QDEL stock, check out TipRanks’ Stock Analysis page.